Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia

BACKGROUND: Patients with 21-hydroxylase deficiency congenital adrenal hyperplasia (21OHD-CAH) have poor health outcomes with increased mortality, short stature, impaired fertility, and increased cardiovascular risk factors such as obesity. To address this, there are therapies in development that ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Prete, Alessandro, Auchus, Richard J, Ross, Richard J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679847/
https://www.ncbi.nlm.nih.gov/pubmed/34735372
http://dx.doi.org/10.1530/EJE-21-0794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679847/
https://www.ncbi.nlm.nih.gov/pubmed/34735372
http://dx.doi.org/10.1530/EJE-21-0794

Ejemplares similares